08:00 | Registration |
|
Proteomics for Personalised Medicine |
| |
08:30 |  | Keynote Presentation A Mouse to Human Search for Cancer Markers
Sam Hanash, Director, McCombs Institute for Cancer Detection and Treatment, University of Texas MD Anderson Cancer Center, United States of America
Despite substantial improvement in our understanding of the molecular pathology of cancer, very limited progress has been made in the molecular diagnostics of cancer. Genomic, transcriptomic and proteomic studies of cancer including the use of mouse models that recapitulate the human disease have provided leads for molecular diagnostics. The prospects of developing a blood based test to detect common cancers at an early stage has been put to test in validation studies using multiple sources of samples. As a result several marker panels have been developed that show promise for detecting early stage cancers. |
|
09:00 | Identification of a Prognostic Protein Profile for Triple Negative Breast Cancer
Arzu Umar, Group Leader, Erasmus Medical Center Rotterdam/Josephine Nefkens Institute, Netherlands
Triple negative breast cancer is very aggressive and no targeted therapies are currently available. We have performed comparative proteome analysis and identified a 15-protein predictor that associates with patient outcome. |
09:30 | Serum Molecular Portraits – Solving the Puzzle of Cancer
Carl Borrebaeck, Professor and Deputy Vice Chancellor, Lund University, Sweden
One of the driving forces in personalized medicine is the search for protein patterns that can be utilized for improved diagnosis, assessing the risk for tumor relapse and disease progression, as well as for evidence based therapy selection. We have designed and developed antibody microarray, a high-throughput technology for protein expression profiling, to the point where it is now generating data for improved diagnosis, patient stratification, risk assessment, as well as giving insights into disease biology. Several clinical studies have been performed, including analysis of serum/plasma/tissue proteomes from patients suffering from e.g. breast cancer, glioblastoma multiforme, pancreatic carcinoma, gastric adenocarcinoma, chronic lymphocytic leukemia, and Non-Hodgkin lymphomas.
The presentation will be focusing on prognostication and risk classification of metastatic breast cancer.
|
|
Proteomics in Development of Anti-Cancer Therapeutics |
| |
10:00 | Kinase Centric Chemical Proteomics Provides Novel Insights into Individual Cancer Biology
Bernhard Kuster, Head, Technical University of Munich, Germany
This presentation focuses on chemical proteomics based on small molecule kinase inhibitor probes and quantitative mass spectrometry to understand individual tumour biology and to identify novel potential drug targets and molecular signalling pathway biomarkers. |
10:30 | Coffee Break & Networking in Exhibition Hall |
11:15 | Proteomic Identification of Putative Biomarkers of Radiotherapy Resistance
Lynn Cawkwell, Senior Lecturer, University of Hull, United Kingdom
Putative biomarkers of radiotherapy resistance have been identified using 3 complementary proteomic platforms. Comparisons between gel-based versus gel-free MS approaches and MS versus non-MS approaches will be highlighted. Progress towards the clinical validation of key proteins will be described. |
|
Secretome Proteomics |
| |
11:45 | Secretome Proteomics for Tumor Biomarker Discovery
Josep Villanueva, Group Leader, Vall d'Hebron Institute of Oncology, Spain
Cancer secretomes are a promising source of tumor biomarkers. The optimization and implementation of secretome proteomics analysis to different cancer research challenges will be presented. |
12:15 | Lunch & Networking in Exhibition Hall |
13:30 | Poster Viewing Session |
14:15 | Characterization of the Metastatic Secretome of Colorectal Cancer
Jose Alvarez, Staff Scientist, Center for Biological Investigation, Spain
Colorectal cancer is the second cause of cancer-associated mortality in developed countries. Tumor metastasis depends on different factors, such as growth factors and receptors, proteases, chemokines and extracellular matrix proteins. Many of these factors are secreted by the metastatic cells. |
|
Cancer Biomarker Development |
| |
14:45 |  | Keynote Presentation Mass Spectrometric Strategies for Protein Biomarker Discovery and Validation
Ruedi Aebersold, Professor, Institute for Systems Biology, United States of America
In this presentation we will discuss this novel biomarker strategy, its present status and expected directions. A case study on PTEN dependent prostate cancer will illustrate the concept. |
|
15:15 | Coffee Break & Networking in Exhibition Hall |
16:00 | Label-Free Mass Spectrometry-Based Proteomics for Cancer Biomarker Discovery and Validation
Connie Jimenez, Head, VU University Medical Center, Netherlands
Label-free mass spectrometry-based proteomics has emerged as a powerful tool for biomarker discovery in biological samples. In my lecture, will present our progress in the discovery and validation of novel screening markers for colorectal cancer and the novel breast cancer signature that selects for homology-repair deficient tumors.
|
16:30 | Clinical Proteomics in Renal Cancer
Peter Selby, Professor of Cancer Medicine, Leeds Institute of Molecular Medicine, United Kingdom
The urgent clinical need for biomarkers for the diagnosis, prognosis, follow up and prediction of response to therapy in renal cancer can be addressed using label-free quantification mass spectrometry and other approaches. Recent progress will be summarised. |
17:00 | Drinks Reception |
